ppat.1009594.s011.docx (27.86 kB)
Overall number and percentage of subjects experiencing systemic or local AEs after any PfSPZ CVac immunization or placebo dose by study group.
journal contribution
posted on 2021-05-28, 17:44 authored by Sean C. Murphy, Gregory A. Deye, B. Kim Lee Sim, Shirley Galbiati, Jessie K. Kennedy, Kristen W. Cohen, Sumana Chakravarty, Natasha KC, Yonas Abebe, Eric R. James, James G. Kublin, Stephen L. Hoffman, Thomas L. Richie, Lisa A. Jackson(DOCX)
History
Usage metrics
Categories
Keywords
malaria increases5.12 x 10 4 PfSPZ-CVacCHMI groupsmalaria infectionblood-stage parasitemiadose escalation trialdose group1.024 x 10 5 PfSPZ-CVacVE warrantvenous inoculationserythrocyte stage parasitemiastudy groupplacebo-controlled trialantimalarial chemoprophylaxisvaccine administrationPfSPZ-CVac efficacyvaccinationDVI 10 weeksgroups proceedinginterval groupClinical trials registrationPlasmodium falciparum sporozoites10 weeksmalaria infection PfSPZ-CVacpreviously-published PfSPZ-CVac study28 daysNCT 02773979
Licence
Exports
RefWorksRefWorks
BibTeXBibTeX
Ref. managerRef. manager
EndnoteEndnote
DataCiteDataCite
NLMNLM
DCDC